deCODE genetics Announces Third Quarter 2008 Financi...(sic and diluted net loss per sha...)

diluted net

loss per share 61,418 61,033 61,353 60,996

Condensed Consolidated Balance Sheet Data

At At

September 30, December 31,

2008 2007

in thousands (unaudited)

Cash and investments ** $ 35,487 $ 94,058

Total

assets 100,244 156,208

Total

liabilities 304,033 301,858

Total shareholders'

equity (203,789) (145,650)

* Other non-operating expense for the three and nine months ended September 30, 2008 principally reflect an unrealized loss resulting from the revaluation of the company's non-current auction rate security investments as of September 30, 2008.

** Cash and investments include cash equivalents, restricted investments and cash equivalents, and non-current investments.

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results, and the timing of events, to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relationships, the effect of a potential delisting of our common stock from The Nasdaq Global Market, uncertainty regarding potential future deterioration in the market for auction rate securities which could negatively affect our cash position and result in additional permanent impairment charges, our ability to develop and marke
'/>"/>